Bevenopran

Summary

Bevenopran (CHEMBL3039511) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including constipation disorder and kidney disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 7
• Chemistry: 386.4 Da · C20H26N4O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3039511
Name	Bevenopran
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	10452732
Molecular formula	C20H26N4O4
Molecular weight	386.4
InChIKey	ZGCYVRNZWGUXNQ-UHFFFAOYSA-N

SMILES: COC1=C(C=CC(=C1)CNCCC2CCOCC2)OC3=NC=C(N=C3)C(=O)N

IUPAC name: 5-[2-methoxy-4-[[2-(oxan-4-yl)ethylamino]methyl]phenoxy]pyrazine-2-carboxamide

Also known as: ADL-5945, ADL5945, Bevenopran, CB-5945, CB5945, BEVENOPRAN

Patent coverage: 42 distinct patent families (127 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
constipation disorder	3	MONDO:0002203	HP:0002019
kidney disorder	1	MONDO:0005240	EFO:0003086

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE3	4
PHASE2	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01696643	PHASE3	TERMINATED	Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
NCT01901302	PHASE3	TERMINATED	Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
NCT01901328	PHASE3	TERMINATED	Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
NCT01901341	PHASE3	TERMINATED	The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
NCT01207427	PHASE2	COMPLETED	Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain
NCT01275755	PHASE2	COMPLETED	Evaluation of the Efficacy and Safety of ADL5945 Once Daily for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain
NCT02508740	PHASE1	TERMINATED	Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).